Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]

• Main Authors: Mareque M (Author), Montesinos P (Author), Font P (Author), Guinea JM (Author), de la Fuente A (Author), Soto J (Author), Oyagüez I (Author), Brockbank J (Author), Iglesias T (Author), Llinares J (Author), Sierra J (Author)
• Format: Book
• Published: Dove Medical Press, 2021-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Mareque M, Montesinos P, Font P, et al. Clinicoecon Outcomes Res. 2021;13:263–277. Page 271, Results, Base Case, second line from the bottom, the text “€ 15,134” should read “€ 151,434”. The authors apologize for this error. Read the original article